HDAC9 and cervical carcinoma: To assess whether HDAC inhibitors can affect the potency of the anticancer drugs in combination treatments, the SiSo human cervical cancer cell line was chosen for further experimentation because of a balanced protein expression among all analyzed HDAC/Sirt isoenzymes (Figure 5).